New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 13, 2014
09:28 EDTGERN, CTICCell Therapeutics to benefit from Geron troubles, says Roth Capital
After Geron's (GERN) telomerase inhibitor for myelofibrosis and other settings was put on full clinical hold due to potential liver injury, Roth Capital thinks that the competitive positioning of Cell Therapeutics' (CTIC) myelofibrosis treatment, Pacritinib, has improved. The firm keeps a Buy rating on Cell Therapeutics.
News For CTIC;GERN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for CTIC;GERN

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use